The combination of bendamustine and rituximab (B-R) should become the preferred first-line therapy for untreated patients with indolent lymphoma and mantle cell lymphoma. The long-term results from a phase III study comparing B-R with standard CHOP-R therapy showed superior efficacy (median progression-free survival of 69.5 versus 31.2 months) and decreased toxicity (no hair loss, and lower neuropathy, infections and hematotoxicity) for the B-R regimen.
ORIGINAL RESEARCH PAPER
Rummel, M. J. et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. J. Clin. Oncol. 30 (Suppl.), LBA3 (2012)
Rights and permissions
About this article
Cite this article
Bendamustine and rituximab triumphs as first-line therapy. Nat Rev Clin Oncol 9, 428 (2012). https://doi.org/10.1038/nrclinonc.2012.107
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.107